Haver

What Haver does

Haver Farma İlaç Anonim Şirketi (operating as Haver Farma or Haver) is a Turkish pharmaceutical manufacturer founded in 1917 as "Tıbbi Müstahzarlar Laboratuvarı" in Çengelköy, Istanbul. The company has evolved over more than 105 years from a small neighborhood pharmacy into a nationally distributed pharmaceutical producer, with operational headquarters in the Beykoz district of Istanbul and 501–1,000 employees. The full legal name is registered in Turkey as an Anonim Şirketi (A.Ş.), the Turkish equivalent of a joint-stock company, and the company is privately held with no identified parent, external PE/VC sponsor, or public stock listing. It has nonetheless published an İzahname (prospectus) dated 15 November 2024, indicating preparation for a potential public offering.

Haver Farma operates two core product verticals: prescription and OTC pharmaceuticals ("İlaç Grubu Ürünleri") and consumer health/dietary supplements ("Tüketici Sağlığı Ürünleri," including vitamins A, C, D3, K2 and other nutritional products). The company emphasizes 100% domestic Turkish manufacturing across multi-thousand-square-meter facilities and sells through pharmacy networks nationwide, targeting healthcare providers, hospitals, clinics, and end consumers. In January 2025, Haver Farma acquired MS Pharma's Turkey production facility, materially expanding manufacturing capacity and enabling domestic localization of three strategic medications previously imported — a move explicitly framed as alignment with Turkish national pharmaceutical self-sufficiency policy. Haver also operates the Haver Akademi educational platform and publishes a "Sağlık Rehberi" (Health Guide) content hub focused on vitamins and supplements.

Commercially, the business runs a sales-led, traditional pharmaceutical distribution model with two revenue streams (prescription pharma sales and consumer supplement sales) routed through domestic pharmacy networks. No public pricing models, revenue figures, or named enterprise customers are disclosed. Recent product launches (including a February 2026 launch titled "Zamana Meydan Okuyan Lansman"), the MS Pharma integration, and the localization initiative are the principal visible drivers of current operating activity.

Name

Haver

Legal name

Haver Farma İlaç Anonim Şirketi

Website

https://haver.com.tr

Company type

Private

Founded year

1917

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Haver Farma is a privately held Turkish pharmaceutical manufacturer founded in 1917, producing 100% domestically made prescription medicines and consumer health/dietary supplements for distribution through pharmacy networks across Turkey.

Ownership category

akta.pro rank

Headquarters

HQ city

Istanbul

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products Sales: Revenue generated from the sale of prescription pharmaceutical products (İlaç Grubu Ürünleri) to pharmacies and healthcare institutions in Turkey.
2. Consumer Health/Supplement Products Sales: Revenue from over-the-counter dietary supplements and consumer health products (Tüketici Sağlığı Ürünleri) sold through pharmacy networks.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Haver Farma manufactures and sells prescription and over-the-counter pharmaceutical products (İlaç Grubu Ürünleri) and consumer health dietary supplements (Tüketici Sağlığı Ürünleri) in Turkey. All products are manufactured domestically with 100% local Turkish investment and distributed through pharmacy networks and healthcare providers nationwide. The company also operates the Haver Akademi educational platform providing health information.

Product overview

Haver Farma is a pharmaceutical company operating in Turkey since 1917, producing dietary supplements and medicines. The company operates two main product categories: Consumer Health Products (Tüketici Sağlığı Ürünleri) consisting of dietary supplements like vitamins and nutritional products, and Pharmaceutical Products (İlaç Grubu Ürünleri) comprising prescription and OTC medications. The company also maintains Haver Akademi as an educational platform for health information. All products are manufactured in Turkey with 100% local investment.

Differentiator

Problem solved

Functional benefit

Brands

• Haver Akademi: Educational and information platform for healthcare professionals and consumers

Products and services

• İlaç Grubu Ürünleri (Pharmaceutical Products)
• Tüketici Sağlığı Ürünleri (Consumer Health Products)

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• MS PharmamajorStrategic or Co-development Partner · 8 January 2025Haver Farma acquired MS Pharma's Turkey production facility in January 2025, significantly expanding its domestic manufacturing capacity. This acquisition represents a major strategic move to localize production of three strategic medications ('Üç Stratejik İlacı Millileştiriyor') and reduce foreign dependency in Turkey's pharmaceutical supply chain.

Scale indicators2 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Santa Farma: Santa Farma is a long-established Turkish pharmaceutical manufacturer (founded 1944) producing prescription medications, OTC products, and consumer health goods. Its heritage-driven positioning and domestic manufacturing focus make it a directly comparable peer to Haver.
• Ali Raif İlaç: Ali Raif İlaç is a Turkish pharmaceutical company producing generic medications and consumer health products distributed through pharmacies. Its mid-sized domestic manufacturing footprint and Rx/supplement portfolio overlap closely with Haver's business model.
• Abdi İbrahim: Abdi İbrahim is one of Turkey's largest pharmaceutical manufacturers, producing both prescription medications and consumer health products for the domestic market. It directly competes with Haver across therapeutic categories and pharmacy distribution channels in Turkey.
• Gensenta İlaç: Gensenta İlaç is a Turkish pharmaceutical manufacturer specializing in generic medications and contract manufacturing for international companies. It directly competes with Haver in the domestic generic drug segment and shares similar contract manufacturing aspirations.
• İlko İlaç: İlko İlaç is a Turkish pharmaceutical manufacturer focused on generic drugs, contract manufacturing, and biopharmaceuticals. It competes with Haver in the domestic prescription drug market and offers similar GMP-compliant manufacturing capabilities.
• Nobel İlaç: Nobel İlaç is a leading Turkish pharmaceutical company producing generic prescription drugs, OTC products, and dietary supplements. It competes directly with Haver in the Turkish pharmacy distribution network across overlapping therapeutic categories.
• Eczacıbaşı İlaç: Eczacıbaşı İlaç is a major Turkish pharmaceutical manufacturer with a portfolio spanning prescription drugs, OTC products, and consumer health supplements. It competes with Haver in the domestic pharmacy channel and shares the same 100% domestic manufacturing positioning.

Broad incumbents

• Bayer Türk: Bayer Türk is the Turkish subsidiary of Bayer AG, operating across pharmaceuticals, consumer health, and crop science. It competes with Haver in OTC, supplement, and prescription categories through broader multinational resources and a wider product portfolio.
• Sandoz: Sandoz is a global leader in generic pharmaceuticals and biosimilars with operations in Turkey. It competes with Haver in the domestic generic and OTC segments and operates a much broader international portfolio, making it an incumbent competitor rather than a direct specialty peer.
• Pfizer Türkiye: Pfizer Türkiye is the Turkish affiliate of Pfizer Inc., one of the world's largest pharmaceutical companies. It competes with Haver across multiple therapeutic categories in the domestic market but operates from a much broader global pipeline and brand portfolio.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@haverfarma
• Facebookfacebook.com/people/Haverfarma/100091078997630
• LinkedInlinkedin.com/company/haverfarma
• Instagraminstagram.com/haverfarma

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Haver